NovAccess Global Files Patent with Cedars-Sinai to Advance its Brain Cancer Fighting Vaccine Platform May 21, 2024 Read More »
NovAccess Global Announces New License to Advance its Immunotherapy Platform April 30, 2024 Read More »
NovAccess Global Provides Business Updates and Announces Scheduling of Annual Meeting of Shareholders March 1, 2024 Read More »
NovAccess Global Inc. to Present at the December 7th Virtual Investor Summit December 2, 2023 Read More »
NovAccess Global Appoints Dr. Roscoe M. Moore, Jr. to Scientific Advisory Board November 10, 2023 Read More »
NovAccess Global Partners with BCN Biosciences to Expand Immunotherapy Platform July 27, 2023 Read More »
NovAccess Global to Participate in National Brain Tumor Society’s Annual Glioblastoma Awareness Day July 13, 2023 Read More »
NovAccess Global Partners with CKN Ventures to Expand its New AI-driven Precision Medicine Division June 16, 2023 Read More »
NovAccess Global Launches Precision Medicine Division Using AI, Big Data and Predictive Technologies to Accelerate Personalized Healthcare Therapies June 1, 2023 Read More »
NovAccess Global Lead Scientist Published in High-Profile Medical Journal for Cancer Vaccine Advancements May 11, 2023 Read More »
Dr. Christopher Wheeler, NovAccess Lead Scientist, Receives Prestigious Golden Axon Award March 15, 2023 Read More »
NovAccess Global Leadership to Present at World Brain Mapping Foundation Annual Congress February 3, 2023 Read More »
NovAccess Global Announces Fireside Chat with Dr. Christopher Wheeler, the Company’s Lead Scientist and President of its StemVax Therapeutics Division January 5, 2023 Read More »
NovAccess Global Announces Initial Fireside Chat with Glioblastoma Patient Advocate November 22, 2022 Read More »
NovAccess Global Receives FDA Approval of Orphan Drug Application for TLR-AD1 October 26, 2022 Read More »
NovAccess Global Announces Fireside Chat Series for the Investment Community September 30, 2022 Read More »
